expressbpdDecember 10, 2018
Tag: AstraZeneca Pharma , Abbott , diabetes drug , Dapagliflozin
AstraZeneca Pharma India has entered into a distribution agreement with Abbott Healthcare for distribution of diabetes medicine Dapagliflozin in India. Dapagliflozin, an innovative Type 2 diabetes medicine, is AstraZeneca Pharma’s leading diabetes medicine.
"Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET," AstraZeneca Pharma said in a regulatory filing.
AstraZeneca Pharma, said it will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo.
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: